Algorx Pharmaceuticals Inc (NASDAQ:AGRX): Institutional Investors Are Worried

September 16, 2018 - By Peter Erickson

Agile Therapeutics, Inc. (NASDAQ:AGRX) Logo

Sentiment for Algorx Pharmaceuticals Inc (NASDAQ:AGRX)

Algorx Pharmaceuticals Inc (NASDAQ:AGRX) institutional sentiment decreased to 0.7 in Q2 2018. Its down -0.42, from 1.12 in 2018Q1. The ratio turned negative, as 14 investment professionals opened new and increased positions, while 20 sold and decreased their stock positions in Algorx Pharmaceuticals Inc. The investment professionals in our partner’s database now hold: 15.95 million shares, down from 23.01 million shares in 2018Q1. Also, the number of investment professionals holding Algorx Pharmaceuticals Inc in their top 10 positions decreased from 4 to 2 for a decrease of 2. Sold All: 12 Reduced: 8 Increased: 8 New Position: 6.

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $12.45 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

The stock decreased 25.36% or $0.123 during the last trading session, reaching $0.362. About 5.79M shares traded or 266.23% up from the average. Agile Therapeutics, Inc. (NASDAQ:AGRX) has declined 84.42% since September 16, 2017 and is downtrending. It has underperformed by 100.04% the S&P500.

Analysts await Agile Therapeutics, Inc. (NASDAQ:AGRX) to report earnings on November, 5. They expect $-0.16 earnings per share, up 27.27 % or $0.06 from last year’s $-0.22 per share. After $-0.16 actual earnings per share reported by Agile Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Proquest Associates Iv Llc holds 3.85% of its portfolio in Agile Therapeutics, Inc. for 5.06 million shares. Investor Ab owns 3.51 million shares or 0.09% of their US portfolio. Moreover, Perceptive Advisors Llc has 0.05% invested in the company for 3.53 million shares. The New York-based Needham Investment Management Llc has invested 0.03% in the stock. Acadian Asset Management Llc, a Massachusetts-based fund reported 86,792 shares.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Coverage

Ratings analysis reveals 100% of Agile Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Agile Therapeutics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $400 while the high is $800. The stock’s average target of $6 is 1557.46% above today’s ($0.362) share price. AGRX was included in 3 notes of analysts from March 29, 2018. H.C. Wainwright maintained Agile Therapeutics, Inc. (NASDAQ:AGRX) on Wednesday, May 9 with “Buy” rating. The company was maintained on Thursday, March 29 by Cantor Fitzgerald. The stock has “Buy” rating by Cantor Fitzgerald on Tuesday, May 8.

More news for Agile Therapeutics, Inc. (NASDAQ:AGRX) were recently published by: Seekingalpha.com, which released: “Agile Therapeutics up 55% premarket” on September 11, 2018. Benzinga.com‘s article titled: “48 Biggest Movers From Yesterday” and published on September 12, 2018 is yet another important article.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>